GGHC
PVLA

Gilder Gagnon Howe & Co’s Palvella Therapeutics PVLA Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-930
Closed -$269K – 302
2019
Q4 		$269K Buy
+930
New +$258K ﹤0.01% 257

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gilder Gagnon Howe & Co's PVLA Position: Q1 2020 in Review

Gilder Gagnon Howe & Co sold out of Palvella Therapeutics (PVLA) in Q1 2020, closing a stake of 930 shares — an estimated $269K sold.

Gilder Gagnon Howe & Co first reported a position in PVLA in Q4 2019 and held it in 1 quarter. The position peaked at $269K in Q4 2019. 95 funds tracked by Wall St. Rank hold PVLA as of Q1 2020.

  • Gilder Gagnon Howe & Co reported no remaining Palvella Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 930 Palvella Therapeutics shares in Q1 2020, an estimated $269K.
  • Gilder Gagnon Howe & Co first reported a position in Palvella Therapeutics in Q4 2019 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Palvella Therapeutics position peaked at $269K in Q4 2019.
  • 95 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2020.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2020, filed 15 May 2020.